Compounds Studied in Skin, Hair and Extracellular-Matrix Research

BPC-157 is a synthetic pentadecapeptide (also written as Body Protection Compound 157), a stable gastric pentadecapeptide fragment derived from a sequence found in human gastric juice; the evidence block does not give its full sequence, formula or molecular weight. GHK is a tripeptide (glycyl-L-histidyl-L-lysine) and GHK-Cu is its copper(II)-bound form; the evidence block does not give a formula or molecular weight for either. Nicotinamide is the amide form of vitamin B3 (niacinamide), and nicotinamide riboside is its riboside. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP receptor agonist; cagrilintide is an amylin analogue; AOD9604 is described in the catalogue as fragment 176-191; ARA-290 is a peptide; 5-Amino-1MQ is a small molecule; Adipotide is a peptide; CJC-1295 with DAC is a growth-hormone-releasing hormone analogue; DSIP is a delta sleep-inducing peptide; Epithalon is a tetrapeptide; Cerebrolysin is a peptide preparation; and bacteriostatic water is a diluent, not an active compound.

The work surveyed here centres on the GLP-1/GIP receptor family, the amylin receptor, the growth-hormone/IGF-1 axis, and the immunoinflammatory and mitochondrial pathways that recur across the cited studies.

Research Studies

BPC-157 and tendon healing after arthroscopic rotator cuff repair

A randomized, double-blind, placebo-controlled pilot trial investigated the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR). Twenty patients undergoing aRCR were enrolled and randomly assigned to receive either BPC-157 or a saline placebo, self-administering subcutaneous injections daily for 90 days following surgery, with all other aspects of care following the standard postoperative pathway. The study notes that BPC-157 is a synthetic peptide that has demonstrated regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury, but that it had not yet been studied in formal human clinical trials [7].

GHK and GHK-Cu and circulating blood levels in healthy adults

A two-part clinical trial investigated GHK and GHK-Cu blood levels pre- and post-intervention in healthy adults, and the efficacy of the X39 patch on GHK and GHK-Cu blood levels compared with placebo. The main questions were the change in GHK and GHK-Cu levels from baseline to Day 8, and the difference in that change between the X39 patch and placebo. Participants completed a questionnaire and used the X39 patch [6].

Nicotinamide and retinal nerve cell protection in primary open-angle glaucoma

The NADIR trial is testing whether a high-dose vitamin B3 supplement called nicotinamide can protect retinal nerve cells in adults with primary open-angle glaucoma (POAG) who are already receiving standard glaucoma eye drops or laser treatment. The main question is whether adding nicotinamide to standard glaucoma therapy slows the rate of thinning of the inner retinal nerve cell layer, measured by a non-invasive eye scan, compared with standard therapy alone over 12 months. Participants were randomly assigned to one of two groups; those in the treatment group took nicotinamide tablets by mouth, starting at a lower dose (1.5 grams per day) [3].

Nicotinamide riboside and walking distance in peripheral artery disease

The NICE-PAD II trial is testing the hypothesis that, among people with peripheral artery disease (PAD) age 50 and older, participants randomized to nicotinamide riboside (NR) will have greater improvement or less decline in six-minute walk distance at six-month follow-up compared with those randomized to placebo. The study randomized 250 participants with PAD age 50 and older to one of two groups for six months: nicotinamide riboside versus placebo. The primary outcome was change in six-minute walk distance at six-month follow-up; secondary outcomes included Walking Impairment Questionnaire (WIQ) distance score, PROMIS Mobility score, and calf muscle perfusion measured by magnetic resonance arterial spin labelling [11].

Semaglutide and cardiometabolic risk after gestational diabetes

An effectiveness-implementation Hybrid Type 1 study using a randomized clinical trial design evaluated the effectiveness and potential real-world integration of immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM). A total of 226 postpartum individuals with recent GDM were randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome, development of metabolic syndrome, was assessed at 6 months postpartum; participants subsequently entered a 6-month maintenance phase during which semaglutide continuation, discontinuation, or initiation reflected patient pathways [2].

Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome

Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options. A multicentre, double-blind, placebo-controlled randomised trial evaluated whether adjunctive oral semaglutide 3 mg once daily, added to treatment as usual, reduces 10-year cardiovascular risk (QRISK3) and improves insulin resistance, lipids, weight and metabolic biomarkers over 24 weeks compared with placebo, while confirming psychiatric safety and tolerability [9].

Tirzepatide and preoperative optimization before one anastomosis gastric bypass

A study compared three preoperative strategies before one anastomosis gastric bypass (OAGB) for severe obesity. Participants were assigned to receive either tirzepatide medication for 60 days, a ketogenic diet for 4 weeks, or standard care before surgery. The main goal was to determine which approach leads to the best weight loss one year after surgery; the study also evaluated safety, surgical outcomes, and improvement of obesity-related health conditions such as diabetes, high blood pressure, and sleep apnea [5].

GLP-1/GIP receptor agonists in obesity-related HFpEF

GLIDE-HF is a prospective, single-center, non-interventional observational cohort registry conducted within routine outpatient heart failure care at a cardiology clinic in Poland. It enrolls patients with obesity-related heart failure with preserved ejection fraction (HFpEF), defined by chronic heart failure symptoms or exertional dyspnea, body mass index at least 30 kg/m2, left ventricular ejection fraction at least 50%, and objective evidence of HFpEF using contemporary diagnostic scores (H2FPEF and HFA-PEFF), without a dominant alternative cause of dyspnea. The registry's guiding principle is that all eligible obesity-related HFpEF patients are enrolled regardless of their treatment [8].

HMB plus vitamin D and muscle preservation in older adults starting semaglutide

A randomized, double-blind, placebo-controlled trial evaluated whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who were newly starting semaglutide as part of usual clinical care. Participants received calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome was change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6; secondary assessments included body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [10].

Mitophagy and mitochondrial DNA dynamics during Ramadan dry fasting versus 16:8 time-restricted feeding

A study investigated how different types of fasting affect cell health, specifically focusing on how mitochondria are cleared and renewed. While standard intermittent fasting allows water intake, Ramadan dry fasting involves total restriction of both food and fluids from dawn to sunset. Researchers examined whether the combined effects of fluid restriction and natural daily body rhythms during Ramadan trigger a stronger cellular cleanup process (called mitophagy) compared to standard 16:8 water-permitted fasting, looking at how these fasting habits change blood markers related to mitochondrial DNA and metabolic health across a 30-day period [4].

AI-assisted subtyping-directed precision treatment in acute aortic dissection

Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. A study integrates multi-dimensional data to construct an AI immunoinflammatory subtyping system, enabling rapid subtyping and establishing a "subtyping-target-treatment" closed loop for emergency needs. Using a prospective multicenter RCT, 300 patients are randomly divided into two groups: the experimental group receives subtyping-based precision therapy, while the control group uses empirical strategies [1].

SYH2069 and glycaemic control in type 2 diabetes

A multicenter, randomized, double-blind, placebo and active-controlled, dose-finding phase 2 study evaluated the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SYH2069 Injection in participants with Type 2 Diabetes Mellitus (T2DM) inadequate glycemic control with diet and exercise alone or metformin monotherapy. The study consisted of four periods: a 2-week screening period, a 3-week run-in period, a 28-week treatment period and a 3-week safety follow-up period. A total of 240 subjects were enrolled, stratified by baseline HbA1c levels (≤8.5% or >8.5%) and prior metformin use (yes or no), then randomized 4:1:4:1:4:1:4:1:4 to SYH [12].

Comparison of cited models and populations

If you are reading this for personal health reasons

The compounds described here are sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection — https://clinicaltrials.gov/study/NCT07382375
• [2] Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes — https://clinicaltrials.gov/study/NCT07797036
• [3] Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) — https://clinicaltrials.gov/study/NCT07808333
• [4] Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding — https://clinicaltrials.gov/study/NCT07638696
• [5] Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery — https://clinicaltrials.gov/study/NCT07622992
• [6] Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults — https://clinicaltrials.gov/study/NCT07706361
• [7] Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery — https://clinicaltrials.gov/study/NCT07803250
• [8] GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry — https://clinicaltrials.gov/study/NCT07787936
• [9] Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome — https://clinicaltrials.gov/study/NCT07770282
• [10] HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide — https://clinicaltrials.gov/study/NCT07760948
• [11] The NICE-PAD II Trial — https://clinicaltrials.gov/study/NCT07782671
• [12] A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin — https://clinicaltrials.gov/study/NCT07796477